258 related articles for article (PubMed ID: 22988100)
1. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho.
Fu T; Choi SE; Kim DH; Seok S; Suino-Powell KM; Xu HE; Kemper JK
Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16137-42. PubMed ID: 22988100
[TBL] [Abstract][Full Text] [Related]
2. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.
Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK
Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity.
Fu T; Kemper JK
Vitam Horm; 2016; 101():175-96. PubMed ID: 27125742
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function.
Fu T; Seok S; Choi S; Huang Z; Suino-Powell K; Xu HE; Kemper B; Kemper JK
Mol Cell Biol; 2014 Nov; 34(22):4130-42. PubMed ID: 25182532
[TBL] [Abstract][Full Text] [Related]
5. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.
Choi SE; Fu T; Seok S; Kim DH; Yu E; Lee KW; Kang Y; Li X; Kemper B; Kemper JK
Aging Cell; 2013 Dec; 12(6):1062-72. PubMed ID: 23834033
[TBL] [Abstract][Full Text] [Related]
6. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.
Gallego-Escuredo JM; Gómez-Ambrosi J; Catalan V; Domingo P; Giralt M; Frühbeck G; Villarroya F
Int J Obes (Lond); 2015 Jan; 39(1):121-9. PubMed ID: 24813368
[TBL] [Abstract][Full Text] [Related]
7. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition.
Lee J; Padhye A; Sharma A; Song G; Miao J; Mo YY; Wang L; Kemper JK
J Biol Chem; 2010 Apr; 285(17):12604-11. PubMed ID: 20185821
[TBL] [Abstract][Full Text] [Related]
8. Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes.
Drexler S; Cai C; Hartmann AL; Moch D; Gaitantzi H; Ney T; Kraemer M; Chu Y; Zheng Y; Rahbari M; Treffs A; Reiser A; Lenoir B; Valous NA; Jäger D; Birgin E; Sawant TA; Li Q; Xu K; Dong L; Otto M; Itzel T; Teufel A; Gretz N; Hawinkels LJAC; Sánchez A; Herrera B; Schubert R; Moshage H; Reissfelder C; Ebert MPA; Rahbari NN; Breitkopf-Heinlein K
Mol Cell Endocrinol; 2023 Jun; 570():111934. PubMed ID: 37085108
[TBL] [Abstract][Full Text] [Related]
9. Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer.
Motylewska E; Stępień T; Borkowska M; Kuzdak K; Siejka A; Komorowski J; Stępień H; Ławnicka H
Cytokine; 2018 May; 105():32-36. PubMed ID: 29438906
[TBL] [Abstract][Full Text] [Related]
10. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a Mediates High-Fat-Induced Hepatic Insulin Resistance by Targeting ENO3.
Wang Y; Zhao X; Zhang L; Yang C; Zhang K; Gu Z; Ding H; Li S; Qin J; Chu X
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960269
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p.
Zhang B; Li H; Li D; Sun H; Li M; Hu H
Gene; 2019 Jun; 700():139-148. PubMed ID: 30898698
[TBL] [Abstract][Full Text] [Related]
13. Role of miR-383 and miR-146b in different propensities to obesity in male mice.
Xia SF; Duan XM; Cheng XR; Chen LM; Kang YJ; Wang P; Tang X; Shi YH; Le GW
J Endocrinol; 2017 Aug; 234(2):201-216. PubMed ID: 28576870
[TBL] [Abstract][Full Text] [Related]
14. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
[TBL] [Abstract][Full Text] [Related]
16. The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis.
Antonellis PJ; Droz BA; Cosgrove R; O'Farrell LS; Coskun T; Perfield JW; Bauer S; Wade M; Chouinard TE; Brozinick JT; Adams AC; Samms RJ
Mol Metab; 2019 Dec; 30():131-139. PubMed ID: 31767164
[TBL] [Abstract][Full Text] [Related]
17. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract][Full Text] [Related]
18. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.
Byun S; Kim DH; Ryerson D; Kim YC; Sun H; Kong B; Yau P; Guo G; Xu HE; Kemper B; Kemper JK
Nat Commun; 2018 Jul; 9(1):2590. PubMed ID: 29968724
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line.
Zhao G; Guo J; Li D; Jia C; Yin W; Sun R; Lv Z; Cong X
DNA Cell Biol; 2013 Dec; 32(12):699-707. PubMed ID: 24050776
[TBL] [Abstract][Full Text] [Related]
20. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
